辛伐他汀在经皮冠脉介入治疗急性心肌梗死中的疗效观察

Therapeutic effects of percutaneous coronary intervention with simvastatin on acute myocardial infarction

目的观察辛伐他汀在急性心肌梗死(AMI)冠脉介入治疗(PCI)中的临床疗效。方法收治的90例AMI患者随机分为观察组和对照组,每组45例。2组均采取常规PCI和AMI治疗方案,观察组加用辛伐他汀进行治疗。比较2组患者PCI围操作期心肌梗死发生率、治疗总有效率,以及血脂、C-反应蛋白(CRP)、B型利肽钠(BNP)、左心室射血分数(LVEF)的变化以及主要心血管不良事件发生情况。结果观察组PCI围操作期心肌梗死发生率为11.1%,对照组为26.7%,差异有统计学意义(P<0.05);观察组治疗总有效率为91.9%,明显高于对照组的55.5%,差异有统计学意义(P<0.05);2组患者治疗后,血脂、CRP、BNP及LVEF均出现了不同程度改善,且观察组优于对照组,差异有统计学意义(P<0.05);观察组主要心血管不良事件发生率为6.67%,明显低于对照组的22.22%,差异有统计学意义(P<0.05)。结论辛伐他汀在急性心肌梗死冠脉介入治疗(PCI)中可使治疗效果提高,同时还可以改善患者血脂水平,减轻心室负荷、降低炎性反应、增加心室功能,降低不良心脏事件的发生,值得推广应用。

Objective To observe the therapeutic effects of percutaneous coronary intervention(PCI)with simvastatin on acute myocardial infarction(AMI).Methods Ninety patients with acute myocardial infarction were randomly divided into observation group and control group,with 45 cases in each group.The patients in both groups were treated by routine PCI and acute myocardial infarction treatment scheme,on that basis,the patients in observation group were treated by simvastatin.The incidence of myocardial infarction during PCI,the total effective rate,and the changes of blood lipids,high-sensitivity C-reactive protein(CRP),B-type lipopeptide sodium(BNP),left ventricular ejection fraction(LVEF),and the incidence of major cardiovascular adverse events were observed and compared between the two groups.Results The incidence rate of myocardial infarction at perioperative period in observation group was 11.1%,which in control group was 26.7%,there was a significant difference between the two groups(P<0.05).The total effective rate in observation group was 91.9%,which in control group was 55.5%,there was a significant difference between the two groups(P<0.05).After treatment the levels of blood lipids,CRP,BNP and LVEF were improved in both groups at different degrees,moreover,the improvement degree in observation group was more significant than that in control group(P<0.05).Moreover the incidence rate of major cardiovascular adverse events in observation group was 6.67%,which in control group was 22.22%,there was a significant difference between the two groups(P<0.05).Conclusion The simvastatin can improve the therapeutic effects on acute myocardial infarction in patients undergoing PCI,moreover,which can improve blood lipid levels,decrease ventricular load,decrease inflammatory response,increase ventricular function,and reduce the incidence of adverse cardiac events,therefor,it is worthy of clinical application and promotion.